128 related articles for article (PubMed ID: 12127866)
1. Changes and challenges--the world post-Gleevec (Glivec).
Hickman JA; Lazo JS
Curr Opin Pharmacol; 2002 Aug; 2(4):357-60. PubMed ID: 12127866
[No Abstract] [Full Text] [Related]
2. Protein tyrosine kinase inhibitors: new treatment modalities?
Fabbro D; Parkinson D; Matter A
Curr Opin Pharmacol; 2002 Aug; 2(4):374-81. PubMed ID: 12127869
[TBL] [Abstract][Full Text] [Related]
3. New drug targets genetic malfunction in chronic myeloid leukemia.
Am J Health Syst Pharm; 2001 Jul; 58(14):1282. PubMed ID: 11471471
[No Abstract] [Full Text] [Related]
4. Imatinib mesylate (STI 571)--a new oral target therapy for chronic myelogenous leukemia (CML).
Chrobák L; Voglová J
Acta Medica (Hradec Kralove); 2003; 46(3):85-9. PubMed ID: 14677715
[TBL] [Abstract][Full Text] [Related]
5. [Molecular targeting therapy of hematopoietic tumors].
Matsumura I; Kanakura Y
Nihon Naika Gakkai Zasshi; 2006 Jul; 95(7):1375-81. PubMed ID: 16893036
[No Abstract] [Full Text] [Related]
6. Targeted cancer therapies in the twenty-first century: lessons from imatinib.
Stegmeier F; Warmuth M; Sellers WR; Dorsch M
Clin Pharmacol Ther; 2010 May; 87(5):543-52. PubMed ID: 20237469
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate: a molecularly targeted therapy for gastrointestinal stromal tumors.
Eisenberg BL
Oncology (Williston Park); 2003 Nov; 17(11):1615-20; discussion 1620, 1623, 1626 passim. PubMed ID: 14682111
[TBL] [Abstract][Full Text] [Related]
8. [Complete remission with imatinib mesylate (Glivec) of an idiopathic hypereosinophilic syndrome associated with a cutaneous mastocytosis after failure of interferon-alpha].
Pottier P; Planchon B; Grossi O
Rev Med Interne; 2003 Aug; 24(8):542-6. PubMed ID: 12888176
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer?
Wiedmann M; Kreth F; Feisthammel J; Deininger M; Mössner J; Caca K
Anticancer Drugs; 2003 Oct; 14(9):751-60. PubMed ID: 14551510
[TBL] [Abstract][Full Text] [Related]
10. Repurposing medicinal compounds for blood cancer treatment.
McCabe B; Liberante F; Mills KI
Ann Hematol; 2015 Aug; 94(8):1267-76. PubMed ID: 26048243
[TBL] [Abstract][Full Text] [Related]
11. The ABL tyrosine kinase inhibitor STI571 (Glivec) in Philadelphia positive acute lymphoblastic leukemia - promises, pitfalls and possibilities.
Ottmann OG; Hoelzer D
Hematol J; 2002; 3(1):2-6. PubMed ID: 11960387
[No Abstract] [Full Text] [Related]
12. [The role of pathologists in the target therapy of gastrointestinal tumors].
Liang ZY
Zhonghua Bing Li Xue Za Zhi; 2010 Jul; 39(7):433-5. PubMed ID: 21055169
[No Abstract] [Full Text] [Related]
13. Pharmacotherapy of gastrointestinal stromal tumours.
Eisenberg BL; von Mehren M
Expert Opin Pharmacother; 2003 Jun; 4(6):869-74. PubMed ID: 12783584
[TBL] [Abstract][Full Text] [Related]
14. Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy.
Okabe S; Tauchi T; Ishii Y; Akahane D; Nunoda K; Honda S; Takaku T; Ohyashiki K
Int J Hematol; 2007 Feb; 85(2):173-4. PubMed ID: 17321998
[No Abstract] [Full Text] [Related]
15. Selective effect of imatinib on serum IgM in a patient with CML.
Nagasawa M; Mizutani S
Int J Hematol; 2004 Nov; 80(4):381-2. PubMed ID: 15615266
[No Abstract] [Full Text] [Related]
16. Granulocytic sarcoma giant in chronic myeloid leukemia during imatinib mesylate therapy.
Rosário Cavalheiro Rde C; Vicari P; Maria Morselli F; Ommati LV; Frazão Rosa Fde O; Rodrigues Oliveira JS
Am J Hematol; 2006 Jan; 81(1):76-7. PubMed ID: 16369975
[No Abstract] [Full Text] [Related]
17. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia.
Pou M; Saval N; Vera M; Saurina A; Solé M; Cervantes F; Botey A
Leuk Lymphoma; 2003 Jul; 44(7):1239-41. PubMed ID: 12916879
[TBL] [Abstract][Full Text] [Related]
18. Optimal duration of adjuvant therapy for patients with resected gastrointestinal stromal tumors.
Blanke CD
JAMA; 2012 Mar; 307(12):1312-4. PubMed ID: 22453573
[No Abstract] [Full Text] [Related]
19. Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia.
Druker B
Semin Hematol; 2001 Jul; 38(3 Suppl 8):9-14. PubMed ID: 11526596
[TBL] [Abstract][Full Text] [Related]
20. Rechallenge of drugs in the era of targeted therapy.
Nishida T; Doi T
Lancet Oncol; 2013 Nov; 14(12):1143-5. PubMed ID: 24140185
[No Abstract] [Full Text] [Related]
[Next] [New Search]
